Literature DB >> 19390974

Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency.

Maria Claudia Peixoto Cenci1, Débora Vieira Soares, Luciana Diniz Carneiro Spina, Rosane Resende de Lima Oliveira Brasil, Priscila Marise Lobo, Vera Aleta Mansur, Jaime Gold, Eduardo Michmacher, Mario Vaisman, Flávia Lúcia Conceição.   

Abstract

The purpose of this study was to evaluate the effects of 5 years of GH substitution on cardiac structure and function, physical work capacity and blood pressure levels in adults with GH deficiency (GHD). Fourteen patients were clinically assessed every 3 months for 5 years. Transthoracic echocardiography and exercise test were performed at baseline, 24, 48 and 60 months. Blood pressure (BP) was measured by means of ambulatory monitoring of blood pressure at baseline, 6, 12, 24 and 60 months. Left ventricular mass and its index increased progressively during the 5 years of GH substitution (P = 0.008 and 0.007, respectively). There were no significant changes in all others cardiac parameters evaluated. It was observed a significant improve in functional capacity (P < 0.001) and maximal oxygen uptake (P = 0.006) during the treatment. Diurnal systolic BP increased by 15 mmHg (P = 0.024) and diurnal diastolic BP by 4.5 mmHg (P = 0.037). There was no change in dirnal systolic pressure load but a considerable but non-statistically significant reduction in diurnal diastolic pressure load was observed during the study. During the night diastolic BP increased by 4 mmHg (P = 0.012) despite a substantial but non-statistically significant reduction in diastolic pressure load. We observed an increase in the proportion of persons with a non-physiological nocturnal fall (non-dippers) throughout the study (from 36.4% at baseline to 54.6% after 60 months of therapy). We concluded that 5 years of GH replacement promoted positive effects on exercise capacity and maximum oxygen uptake in spite of a modest increase in BP levels and left ventricular mass. Continuous monitoring is mandatory to arrive at further conclusions concerning the effects of GH substitution in adults on cardiovascular parameters with respect to possible unfavorable long term effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390974     DOI: 10.1007/s11102-009-0182-2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  48 in total

1.  Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.

Authors:  Celina Franco; Gudmundur Johannsson; Bengt-Ake Bengtsson; Johan Svensson
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

2.  Serum lipids in acromegaly.

Authors:  E A Nikkilä; R Pelkonen
Journal:  Metabolism       Date:  1975-07       Impact factor: 8.694

Review 3.  ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing).

Authors:  R J Gibbons; G J Balady; J W Beasley; J T Bricker; W F Duvernoy; V F Froelicher; D B Mark; T H Marwick; B D McCallister; P D Thompson; W L Winters; F G Yanowitz; J L Ritchie; R J Gibbons; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R P Lewis; R A O'Rourke; T J Ryan
Journal:  J Am Coll Cardiol       Date:  1997-07       Impact factor: 24.094

4.  The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study.

Authors:  Annamaria Colao; Carolina di Somma; Rosario Pivonello; Alberto Cuocolo; Letizia Spinelli; Domenico Bonaduce; Marco Salvatore; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

5.  The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency.

Authors:  A Minczykowski; M Gryczynska; K Ziemnicka; R Czepczynski; J Sowinski; H Wysocki
Journal:  Growth Horm IGF Res       Date:  2005-04       Impact factor: 2.372

Review 6.  Growth hormone deficiency and cardiovascular risk.

Authors:  F L Hew; D O'Neal; N Kamarudin; F P Alford; J D Best
Journal:  Baillieres Clin Endocrinol Metab       Date:  1998-07

7.  Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.

Authors:  A Colao; C di Somma; A Cuocolo; L Spinelli; N Tedesco; R Pivonello; D Bonaduce; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.

Authors:  V Markussis; S A Beshyah; C Fisher; P Sharp; A N Nicolaides; D G Johnston
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

9.  The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis.

Authors:  W Matthew Widdowson; James Gibney
Journal:  J Clin Endocrinol Metab       Date:  2008-08-12       Impact factor: 5.958

10.  Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults.

Authors:  L Thuesen; J O Jørgensen; J R Müller; B O Kristensen; N E Skakkebaek; N Vahl; J S Christiansen
Journal:  Clin Endocrinol (Oxf)       Date:  1994-11       Impact factor: 3.478

View more
  9 in total

1.  Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study.

Authors:  Mikkel Andreassen; Jens Faber; Andreas Kjaer; Claus Leth Petersen; Lars Østergaard Kristensen
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 2.  [Growth hormone therapy in adult patients: a review].

Authors:  Peter Herbert Kann
Journal:  Wien Klin Wochenschr       Date:  2011-05-18       Impact factor: 1.704

3.  Cardiac functions in children with growth hormone deficiency before and during growth hormone-replacement therapy.

Authors:  Osman Ozdemir; Ayhan Abaci; Samil Hizli; Cem Hasan Razi; Ahmet Zulfikar Akelma; Mesut Kocak; Fatih Mehmet Kislal
Journal:  Pediatr Cardiol       Date:  2011-04-07       Impact factor: 1.655

4.  Systemic hypertension counteracts potential benefits of growth hormone replacement therapy on left ventricular remodeling in adults with growth hormone deficiency.

Authors:  C de Gregorio; L Curtò; F Marini; G Andò; O Trio; F Trimarchi; S Coglitore; S Cannavò
Journal:  J Endocrinol Invest       Date:  2012-10-15       Impact factor: 4.256

Review 5.  Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2018-02-07       Impact factor: 3.633

6.  Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance.

Authors:  Julia D J Thomas; Abhishek Dattani; Filip Zemrak; Thomas Burchell; Scott A Akker; Mark Gurnell; Ashley B Grossman; L Ceri Davies; Márta Korbonits
Journal:  Endocrine       Date:  2016-08-17       Impact factor: 3.633

7.  Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency.

Authors:  Ming Chen; Dongmei Gan; Yili Luo; Sharvan Rampersad; Lu Xu; Shaoling Yang; Nan Li; Hong Li
Journal:  Pediatr Res       Date:  2018-01-17       Impact factor: 3.756

8.  Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency.

Authors:  S Gonzalez; J D Windram; T Sathyapalan; Z Javed; A L Clark; S L Atkin
Journal:  J Int Med Res       Date:  2017-08-31       Impact factor: 1.671

Review 9.  The Use and Abuse of Human Growth Hormone in Sports.

Authors:  David M Siebert; Ashwin L Rao
Journal:  Sports Health       Date:  2018-06-22       Impact factor: 3.843

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.